1
|
Xu LH, Yang Y, Liu HX, Xiao SF, Qiu WX, Wang JX, Zhao CC, Gui YH, Liu GZ, Peng B, Li X, Wang GH, Zhou X, Jiang ZL. Inner Ear Arginine Vasopressin-Vasopressin Receptor 2-Aquaporin 2 Signaling Pathway Is Involved in the Induction of Motion Sickness. J Pharmacol Exp Ther 2020; 373:248-260. [PMID: 32165443 DOI: 10.1124/jpet.119.264390] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/09/2019] [Accepted: 02/24/2020] [Indexed: 11/22/2022] Open
Abstract
It has been identified that arginine vasopressin (AVP), vasopressin receptor 2(V2R), and the aquaporin 2 (AQP2) signaling pathway in the inner ear play important roles in hearing and balance functions through regulating the endolymph equilibrium; however, the contributions of this signaling pathway to the development of motion sickness are unclear. The present study was designed to investigate whether the activation of the AVP-V2R-AQP2 signaling pathway in the inner ear is involved in the induction of motion sickness and whether mozavaptan, a V2R antagonist, could reduce motion sickness. We found that both rotatory stimulus and intraperitoneal AVP injection induced conditioned taste aversion (a confirmed behavioral index for motion sickness) in rats and activated the AVP-V2R-AQP2 signaling pathway with a responsive V2R downregulation in the inner ears, and AVP perfusion in cultured epithelial cells from rat endolymphatic sacs induced similar changes in this pathway signaling. Vestibular training, V2R antagonist mozavaptan, or PKA inhibitor H89 blunted these changes in the V2R-AQP2 pathway signaling while reducing rotatory stimulus- or DDAVP (a V2R agonist)-induced motion sickness in rats and dogs. Therefore, our results suggest that activation of the inner ear AVP-V2R-AQP2 signaling pathway is potentially involved in the development of motion sickness; thus, mozavaptan targeting AVP V2Rs in the inner ear may provide us with a new application option to reduce motion sickness. SIGNIFICANCE STATEMENT: Motion sickness affects many people traveling or working. In the present study our results showed that activation of the inner ear arginine vasopressin-vaspopressin receptor 2 (V2R)-aquaporin 2 signaling pathway was potentially involved in the development of motion sickness and that blocking V2R with mozavaptan, a V2R antagonist, was much more effective in reducing motion sickness in both rat and dog; therefore, we demonstrated a new mechanism to underlie motion sickness and a new candidate drug to reduce motion sickness.
Collapse
Affiliation(s)
- Li-Hua Xu
- Department of Neurophysiology and Neuropharmacology, Institute of Special Environmental Medicine, Institute of Nautical Medicine and Co-innovation Center of Neuroregeneration, Nantong University, Nantong, Jiangsu, China
| | - Yao Yang
- Department of Neurophysiology and Neuropharmacology, Institute of Special Environmental Medicine, Institute of Nautical Medicine and Co-innovation Center of Neuroregeneration, Nantong University, Nantong, Jiangsu, China
| | - Hong-Xia Liu
- Department of Neurophysiology and Neuropharmacology, Institute of Special Environmental Medicine, Institute of Nautical Medicine and Co-innovation Center of Neuroregeneration, Nantong University, Nantong, Jiangsu, China
| | - Shui-Feng Xiao
- Department of Neurophysiology and Neuropharmacology, Institute of Special Environmental Medicine, Institute of Nautical Medicine and Co-innovation Center of Neuroregeneration, Nantong University, Nantong, Jiangsu, China
| | - Wen-Xia Qiu
- Department of Neurophysiology and Neuropharmacology, Institute of Special Environmental Medicine, Institute of Nautical Medicine and Co-innovation Center of Neuroregeneration, Nantong University, Nantong, Jiangsu, China
| | - Jin-Xing Wang
- Department of Neurophysiology and Neuropharmacology, Institute of Special Environmental Medicine, Institute of Nautical Medicine and Co-innovation Center of Neuroregeneration, Nantong University, Nantong, Jiangsu, China
| | - Chen-Chen Zhao
- Department of Neurophysiology and Neuropharmacology, Institute of Special Environmental Medicine, Institute of Nautical Medicine and Co-innovation Center of Neuroregeneration, Nantong University, Nantong, Jiangsu, China
| | - Yuan-Hong Gui
- Department of Neurophysiology and Neuropharmacology, Institute of Special Environmental Medicine, Institute of Nautical Medicine and Co-innovation Center of Neuroregeneration, Nantong University, Nantong, Jiangsu, China
| | - Gui-Zhu Liu
- Department of Neurophysiology and Neuropharmacology, Institute of Special Environmental Medicine, Institute of Nautical Medicine and Co-innovation Center of Neuroregeneration, Nantong University, Nantong, Jiangsu, China
| | - Bin Peng
- Department of Neurophysiology and Neuropharmacology, Institute of Special Environmental Medicine, Institute of Nautical Medicine and Co-innovation Center of Neuroregeneration, Nantong University, Nantong, Jiangsu, China
| | - Xia Li
- Department of Neurophysiology and Neuropharmacology, Institute of Special Environmental Medicine, Institute of Nautical Medicine and Co-innovation Center of Neuroregeneration, Nantong University, Nantong, Jiangsu, China
| | - Guo-Hua Wang
- Department of Neurophysiology and Neuropharmacology, Institute of Special Environmental Medicine, Institute of Nautical Medicine and Co-innovation Center of Neuroregeneration, Nantong University, Nantong, Jiangsu, China
| | - Xin Zhou
- Department of Neurophysiology and Neuropharmacology, Institute of Special Environmental Medicine, Institute of Nautical Medicine and Co-innovation Center of Neuroregeneration, Nantong University, Nantong, Jiangsu, China
| | - Zheng-Lin Jiang
- Department of Neurophysiology and Neuropharmacology, Institute of Special Environmental Medicine, Institute of Nautical Medicine and Co-innovation Center of Neuroregeneration, Nantong University, Nantong, Jiangsu, China
| |
Collapse
|
2
|
Turan M, Ciğer E, Arslanoğlu S, Börekci H, Önal K. Could edaravone prevent gentamicin ototoxicity? An experimental study. Hum Exp Toxicol 2016; 36:123-127. [PMID: 27022163 DOI: 10.1177/0960327116639360] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
OBJECTIVES Clinical application of gentamicin may cause nephrotoxicity and ototoxicity. Our study is the first study to investigate the protective effects of edaravone against the gentamicin-induced ototoxicity. We investigated the protective effect of intraperitoneal (i.p.) edaravone application against gentamicin-induced ototoxicity in guinea pigs. METHODS Fourteen guinea pigs were divided into two equal groups consisting of a control group and a study group. One-hundred sixty milligrams per kilogram subcutaneous gentamicin and 0.3 mL i.p. saline were applied simultaneously once daily to seven guinea pigs in the control group (group 1). One-hundred sixty milligrams per kilogram gentamicin was applied subcutaneously and 3 mg/kg edaravone was applied intraperitoneally once daily for 7 days simultaneously to seven guinea pigs in the study group (group 2). Following the drug application, auditory brainstem response measurements were performed for the left ear on the 3rd and 7th days. RESULTS Hearing threshold values of the group 1 and group 2 measured in the 3rd day of the study were detected as 57.14 ± 4.88 and 82.86 ± 7.56, respectively. This difference was statistically significant ( p < 0.05). Hearing threshold values of the group 1 and group 2 measured in the 7th day of the study were detected as 87.14 ± 4.88 and 62.86 ± 4.88, respectively. This difference was statistically significant ( p < 0.05). CONCLUSION A statistically significant difference between the average threshold values of edaravone-administered group 2 and that of group 1 without edaravone was found. These differences show that systemic edaravone administration could diminish ototoxic effects of gentamicin and the severity of the hearing loss.
Collapse
Affiliation(s)
- M Turan
- 1 Department of Otolaryngology-Head and Neck Surgery, Faculty of Medicine, Yüzüncü Yıl University, Van, Turkey
| | - E Ciğer
- 2 Department of Otolaryngology-Head and Neck Surgery, Ataturk Training and Research Hospital, Katip Celebi University, Izmir, Turkey
| | - S Arslanoğlu
- 2 Department of Otolaryngology-Head and Neck Surgery, Ataturk Training and Research Hospital, Katip Celebi University, Izmir, Turkey
| | - H Börekci
- 3 Department of General Surgery, Faculty of Medicine, Bozok University, Yozgat, Turkey
| | - K Önal
- 2 Department of Otolaryngology-Head and Neck Surgery, Ataturk Training and Research Hospital, Katip Celebi University, Izmir, Turkey
| |
Collapse
|
3
|
Im GJ, Chang J, Lee S, Choi J, Jung HH, Lee HM, Ryu SH, Park SK, Kim JH, Kim HJ. Protective role of edaravone against cisplatin-induced ototoxicity in an auditory cell line. Hear Res 2015; 330:113-8. [DOI: 10.1016/j.heares.2015.08.004] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/23/2015] [Revised: 07/31/2015] [Accepted: 08/12/2015] [Indexed: 10/23/2022]
|
4
|
Choi J, Kim SH, Rah YC, Chae SW, Lee JD, Lee BD, Park MK. Effects of caffeic acid on cisplatin-induced hair cell damage in HEI-OC1 auditory cells. Int J Pediatr Otorhinolaryngol 2014; 78:2198-204. [PMID: 25458160 DOI: 10.1016/j.ijporl.2014.10.013] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/10/2014] [Revised: 09/22/2014] [Accepted: 10/10/2014] [Indexed: 10/24/2022]
Abstract
INTRODUCTION Cisplatin is a widely used anticancer chemotherapeutic agent. However, it is notorious for its ototoxicity and nephrotoxicity due to induction of reactive oxygen species (ROS). Caffeic acid is a naturally occurring polyphenol present in honey that is known to reduce the generation of oxygen-derived free radicals. The objective of the present study was to evaluate the protective effects and mechanism underlying the effect of caffeic acid on cisplatin-induced ototoxicity in HEI-OC1 auditory cell lines. METHODS Cell viability was measured using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. Apoptosis was determined by Hoechst 33258 staining and Annexin V-fluorescein isothiocyanate/propidium iodide double staining. Cell cycle stages were analyzed by flow cytometry. The radical-scavenging activity of caffeic acid was assessed using the 1,1-diphenyl-2-picrylhydrazyl (DPPH) assay. The expression levels of caspase-3, -8, and -9, as well as the activity of caspase-3, were evaluated. RESULTS Caffeic acid showed a protective effect against cisplatin-induced HEI-OC1 cell damage as demonstrated by the MTT assay. Caffeic acid decreased cell death by apoptosis and necrosis. Caffeic acid showed strong scavenging activity against the radical DPPH and decreased intracellular ROS production. Caffeic acid decreased the expression of caspase-3 and -8 and increased the activity of caspase-3. CONCLUSIONS Caffeic acid attenuated cisplatin-induced hair cell loss in HEI-OC1 cell lines; these effects were mediated by its radical scavenging activity and inhibition of apoptosis.
Collapse
Affiliation(s)
- June Choi
- Department of Otorhinolaryngology-Head and Neck Surgery, Korea National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea
| | - Shin Hye Kim
- Department of Otorhinolaryngology-Head and Neck Surgery, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea
| | - Yoon Chan Rah
- Department of Otorhinolaryngology-Head and Neck Surgery, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea
| | - Sung Won Chae
- Department of Otorhinolaryngology-Head and Neck Surgery, Korea National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea
| | - Jong Dae Lee
- Department of Otorhinolaryngology-Head and Neck Surgery, Soonchunhyang National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea
| | - Byung Don Lee
- Department of Otorhinolaryngology-Head and Neck Surgery, Soonchunhyang National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea
| | - Moo Kyun Park
- Department of Otorhinolaryngology-Head and Neck Surgery, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea.
| |
Collapse
|
5
|
Choi J, Chang J, Jun HJ, Im GJ, Chae SW, Lee SH, Kwon SY, Jung HH, Chung AY, Park HC. Protective role of edaravone against neomycin-induced ototoxicity in zebrafish. J Appl Toxicol 2014; 34:554-61. [PMID: 24795994 DOI: 10.1002/jat.2964] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
Aminoglycosides such as neomycin are one of the most commonly prescribed types of antibiotics worldwide. However, these drugs appear to generate free radicals within the inner ear, which can result in permanent hearing loss. We evaluated the effects of edaravone, a neuroprotective agent, on neomycin-induced ototoxicity in transgenic zebrafish. The 5-day post fertilization (dpf) zebrafish larvae were exposed to 125 μM neomycin and various concentrations of edaravone for 1 h. Hair cell survival was calculated as average numbers of the hair cells in the control group, which was not exposed to neomycin. Ultrastructural changes were evaluated using a scanning electron microscope (SEM) and transmission electron microscope (TEM). Edaravone protected against neomycin-induced hair cell loss in the neuromasts (1000 μM: 11.6 ± 1.1 cells, neomycin only: 5.5 ± 0.5 cells; n = 10, P<0.05) and decreased the TUNEL reaction for detecting apoptosis. In ultrastructural analysis, structures of mitochondria and hair cells within neuromasts were preserved in zebrafish exposed to 125 μM neomycin and 1000 μM edaravone for 1 h. Edaravone protected against neomycin-induced hair cell loss by preventing apoptosis.
Collapse
MESH Headings
- Animals
- Animals, Genetically Modified
- Antipyrine/analogs & derivatives
- Antipyrine/pharmacology
- Apoptosis/drug effects
- Cells, Cultured
- Dose-Response Relationship, Drug
- Edaravone
- Embryo, Nonmammalian/drug effects
- Embryo, Nonmammalian/ultrastructure
- Hair Cells, Auditory/drug effects
- Hair Cells, Auditory/ultrastructure
- In Situ Nick-End Labeling
- Microscopy, Confocal
- Microscopy, Electron, Scanning
- Microscopy, Electron, Transmission
- Mitochondria/drug effects
- Mitochondria/ultrastructure
- Neomycin/toxicity
- Neuroprotective Agents/pharmacology
- Zebrafish/embryology
- Zebrafish/genetics
Collapse
|
6
|
Inoue Y, Yabe T, Okada K, Nakamura Y. Effect of edaravone on acute brainstem–cerebellar infarction with vertigo and sudden hearing loss. Auris Nasus Larynx 2014; 41:303-6. [DOI: 10.1016/j.anl.2013.10.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/15/2013] [Revised: 09/26/2013] [Accepted: 10/04/2013] [Indexed: 11/29/2022]
|
7
|
Hong SJ, Im GJ, Chang J, Chae SW, Lee SH, Kwon SY, Jung HH, Chung AY, Park HC, Choi J. Protective effects of edaravone against cisplatin-induced hair cell damage in zebrafish. Int J Pediatr Otorhinolaryngol 2013; 77:1025-31. [PMID: 23628221 DOI: 10.1016/j.ijporl.2013.04.003] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/20/2012] [Revised: 03/31/2013] [Accepted: 04/06/2013] [Indexed: 10/26/2022]
Abstract
OBJECTIVE Edaravone is known to have a potent free radical scavenging effect. The objective of the present study was to evaluate the effects of edaravone on cisplatin-induced ototoxicity in transgenic zebrafish (Brn3C: EGFP). METHODS Five day post-fertilization zebrafish larvae were exposed to 1000 μM cisplatin and 50 μM, 100 μM, 250 μM, 500 μM, 750 μM, and 1000 μM concentrations of edaravone for 4h. Hair cells within neuromasts of the supraorbital (SO1 and SO2), otic (O1), and occipital (OC1) lateral lines were analyzed by fluorescence microscopy and confocal microscopy (n=10). Hair cell survival was calculated as a percentage of the hair cells in the control group that were not exposed to cisplatin. Ultrastructural changes were evaluated using scanning electron microscopy and transmission electron microscopy. RESULTS Edaravone protected cisplatin-induced hair cell loss of neuromasts (edaravone 750 μM: 8.7 ± 1.5 cells, cisplatin 1000 μM only: 3.7 ± 0.9 cells; n=10, p<0.0001) and decreased the Terminal deoxynucleotidyl transferase (TdT)-mediated dUTP-biotin nick end labeling (TUNEL) reaction. Structures of mitochondria and hair cell within neuromasts in ultrastructural analysis were preserved in zebrafish exposed to 1000 μM cisplatin and 750 μM edaravone for 4h. CONCLUSIONS Edaravone attenuated cisplatin-induced hair cell damage in zebrafish. The results of the current study suggest that cisplatin induces apoptosis, and the apoptotic cell death can be prevented by treatment with edaravone in zebrafish.
Collapse
Affiliation(s)
- Seok Jin Hong
- Department of Otorhinolaryngology-Head and Neck Surgery, Korea University College of Medicine, Ansan-City, South Korea
| | | | | | | | | | | | | | | | | | | |
Collapse
|
8
|
Asplund MS, Lidian A, Linder B, Takumida M, Anniko M. Protective effect of edaravone against tobramycin-induced ototoxicity. Acta Otolaryngol 2009; 129:8-13. [PMID: 18607936 DOI: 10.1080/00016480802008199] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
Abstract
CONCLUSION It is suggested that simultaneous treatment with the radical scavenger edaravone has an effective protective effect against tobramycin ototoxicity in rat. Even if the edaravone treatment is postponed for 7 days, it can still prevent hearing loss, but a 14 day delay cannot protect from ototoxicity. OBJECTIVES With the aim of alleviating hearing loss caused by aminoglycoside ototoxicity, we performed a trial to assess the hearing protective efficacy of the radical scavenger edaravone. MATERIALS AND METHODS In part one of the study, 21 male Sprague-Dawley albino rats were used; 2 rats served as controls for the safety of edaravone. Eight rats each received 10 subcutaneous injections (s.c.) of tobramycin (160 mg/kg b.w.) once daily and saline injection intraperitoneally for 2 weeks. Eleven rats were given 10 s.c. tobramycin injections simultaneously with an intraperitoneal injection of edaravone (3 mg/kg b.w.). In part two, tobramycin was injected in 13 rats (as above). Five of these received two edaravone injections 7 days later and four rats similarly 14 days later. Auditory brainstem response (ABR) was used to assess hearing. RESULTS All rats treated only with tobramycin showed a deterioration of hearing. None of the rats given simultaneous treatment with tobramycin and edaravone demonstrated hearing loss. A 7 day delay in edaravone injection still prevented hearing loss, but a 14 day delay had only a temporary prophylactic effect.
Collapse
|
9
|
Abstract
Over the last decade, important advances have been made to support the fact that reactive oxygen species (ROS) are generated and play a harmful role during the acute and late stages of cerebral ischemia. Several drugs, such as radical scavengers and antioxidants, have been evaluated in preclinical and clinical studies. Edaravone (3-methyl-1-phenyl-2-pyrazolin-5-one; Radicut, Mitsubishi Tanabe Pharma Corporation) is a novel antioxidant that is currently used in Japan for the treatment of patients in the acute stage of cerebral infarction. Edaravone scavenges ROS and inhibits proinflammatory responses after brain ischemia in animals and humans. In particular, postischemic inflammation, leading to brain edema and infarction due to neuronal damage and endothelial cell death, can be ameliorated by edaravone. In addition to these antistroke effects, edaravone has also been shown to prevent oxidative damage to various extracerebral organs. Therefore, in addition to its usefulness in the treatment of stroke, edaravone is expected to play an integral role in the treatment of many oxidative stress-related diseases.
Collapse
Affiliation(s)
- Toshiaki Watanabe
- Department of REDOX Medicinal Science, Graduate School of Pharmaceutical Sciences, Kyushu University, Fukuoka, Japan.
| | | | | |
Collapse
|